Linked Life Data

3519244

Source:http://linkedlifedata.com/resource/pubmed/id/3519244

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1986-7-7
pubmed:abstractText
The effect of a new alpha-glucosidase inhibitor (BAY m 1099), a 1-deoxynojirimycin derivative, was studied in 10 black patients with Type II diabetes mellitus. It produced significant lowering of blood glucose concentration after standardized maize porridge meals. No significant untoward effects were noted. BAY m 1099 appears to offer potential benefit in the management of Type II diabetics, and more extensive clinical investigation is warranted.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0031-6970
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
253-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't